Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Low-Dose Quetiapine in the Treatment of Ssri-Induced Bruxism and Mandibular Dystonia: Case Series



Zandifar A1 ; Mohammadi MR2 ; Badrfam R3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Imam Hossein Hospital, Alborz University of Medical Sciences, Karaj, Iran
  2. 2. Psychiatry and Psychology Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Psychiatry Published:2018

Abstract

Objective: Selective serotonin reuptake inhibitors (SSRIs) have been the most widely used psychopharmacological agents prescribed for depression worldwide. Some adverse effects of SSRI drugs on central nervous system are insomnia and bruxism. These drugs also affect sleep. Quetiapine is used as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). It is a low- dose dibenzothiazepine with more potent 5-HT2 than D2 receptor-blocking properties that can be used to manage bruxism because of its antagonist effect on the 5-HT2 receptor. Cases: The cases were 5 patients who have recently been treated with SSRIs and presented with bruxism. Low- dose quetiapine (between 25 and 50 mg daily) was prescribed for the patients, and after a few days, they reported no bruxism and continued taking the medication. Conclusion: We found that quetiapine can improve bruxism and mandibular dystonia, which are side effects of SSRIs. © 2018 Tehran University of Medical Sciences.